Onconetix (ONCO) Net Margin (2024 - 2026)
Onconetix (ONCO) posted quarterly Net Margin of 6426.4% for Q4 2025, up 1059012.0% year-over-year from N/an in Q4 2024, and up 322.16% quarter-over-quarter from 2892.7% in Q3 2025.
Onconetix (ONCO) Net Margin (2024 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Net Margin for 2 consecutive years, with 6426.4% the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Margin rose 1059012.0% year-over-year to 6426.4%; the TTM figure through Mar 2026 stood at 2012.53% (up 98696.0% YoY), while the FY2025 annual figure was 2588.49%, down 25510.0% from the prior year.
- Net Margin advanced to 6426.4% in Q4 2025 per ONCO's latest filing, from 2892.7% in the prior quarter.
- Across five years, Net Margin topped out at 6426.4% in Q4 2025 and bottomed at 9715.98% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | -16,748.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16,748.27% |
| Mar 31, 2026 | -19,643.36% |
| Dec 31, 2025 | 6,426.40% |
| Sep 30, 2025 | -2,892.70% |
| Jun 30, 2025 | -2,536.24% |
| Mar 31, 2025 | -9,715.98% |
| Dec 31, 2024 | -4,163.73% |
| Sep 30, 2024 | -956.85% |
| Jun 30, 2024 | -2,029.76% |
| Mar 31, 2024 | -1,587.39% |